Medical Weight Loss at Med Spas: GLP-1 Programs, Costs and Who Can Prescribe

Medical weight loss is the name the industry gives to weight treatment that runs on prescription medicine and clinical supervision, and the same phrase covers everything from an obesity-medicine practice to a med spa's weight program.

We could not confirm any standard definition or required checklist for the phrase, so treat it as a label to unpack rather than a promise of contents.

The floor is set by the prescriptions themselves: FDA says Wegovy, Zepbound and Foundayo need a valid prescription from a licensed prescriber, and that patients should fill those prescriptions at a state-licensed pharmacy.

Any program offering these drugs is built on that requirement, whatever else it bundles around it.

The labels also build food and activity into the treatment.

Zepbound is approved for use with a reduced-calorie diet and increased physical activity, and Wegovy with diet and activity.

A program that skips that half is not delivering the regimen the drugs were approved with.

Medical weight loss is also a different category from body contouring.

Allergan's own consumer safety information says CoolSculpting and CoolSculpting Elite are not treatments for weight loss.

What differs between clinics is the wrapper: whether the monthly price bundles the medication, the prescriber visit, lab work and follow-up, or bills each separately.

We could not confirm a standard structure, so ask a clinic to itemize in writing what its fee covers before you pay anything.

The branded prescription medicines this page covers are the three our research records as FDA-approved for weight-related uses: Wegovy, Zepbound and Foundayo.

Two come as injections and one as a tablet — and Wegovy now comes in both forms.

• Wegovy (semaglutide, Novo Nordisk). Approved, with diet and activity, to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; to reduce and maintain excess body weight in adults and children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition; and, under accelerated approval, for noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3) in adults.
• Wegovy tablets. Semaglutide 25 mg once daily is also approved for weight reduction and cardiovascular risk reduction in adults; the label's indications were updated in December 2025.
• Zepbound (tirzepatide, Eli Lilly). Approved, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain the reduction long term in adults with obesity, or adults with overweight plus at least one weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.
• Foundayo (orforglipron, Eli Lilly). A once-daily oral, non-peptide GLP-1 receptor agonist first approved in 2026 for chronic weight management in adults with obesity or overweight plus a weight-related condition; it can be taken with or without food.

The molecules are not interchangeable: tirzepatide acts on both the GIP receptor and the GLP-1 receptor, while semaglutide acts on the GLP-1 receptor alone.

Two familiar names are not on the list.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes — glycemic control, cardiovascular risk reduction and kidney-outcome risk reduction — and Mounjaro (tirzepatide) is approved for type 2 diabetes as well.

Ozempic is not FDA-approved for weight loss; using it for weight is off-label, meaning that use is not on any current US label for the product.

On results, the headline trials tested the top doses over long horizons in adults without diabetes:

• SURMOUNT-1 (2,539 adults): mean weight change at 72 weeks was -15.0% on 5 mg of tirzepatide weekly, -19.5% on 10 mg and -20.9% on 15 mg, against -3.1% on placebo.
• STEP 1: mean body-weight change at 68 weeks was -14.9% with semaglutide 2.4 mg, against -2.4% on placebo; 86.4% of semaglutide participants lost at least 5% and 50.5% lost at least 15%.
• The Foundayo label's 72-week trial: mean weight change was -11.1% on the 17.2 mg daily dose, against -2.1% on placebo.

Start with who the labels cover.

Zepbound's weight indication is adults with obesity, or adults with overweight plus at least one weight-related condition.

Wegovy injection covers those adult groups and adds children aged 12 and older with obesity; the tablets are approved for adults only.

Foundayo covers adults with obesity or overweight plus a weight-related condition.

Whether you fit a group is a licensed prescriber's determination to make with your history in hand.

Both injectable products' labels also name a hard exclusion: a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Zepbound is contraindicated in patients with either, and Wegovy is contraindicated with a personal or family history of MTC or MEN 2 as well.

Pregnancy and breastfeeding have label rules of their own.

The Wegovy label says to stop when pregnancy is recognized and to discontinue at least 2 months before a planned pregnancy because of semaglutide's long half-life, and breastfeeding is not recommended while taking Wegovy tablets.

The Zepbound label says tirzepatide may reduce the effectiveness of oral birth control and advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase; it should also be stopped when pregnancy is recognized.

The labels carry a longer warning list beyond that.

Zepbound's includes severe GI reactions (it is not recommended in severe gastroparesis), acute kidney injury from dehydration, gallbladder disease, acute pancreatitis, serious allergic reactions, hypoglycemia when combined with insulin or sulfonylureas, diabetic retinopathy complications, and pulmonary aspiration under anesthesia or deep sedation.

The Wegovy label reports gallstones in 1.6% of Wegovy injection patients versus 0.7% on placebo, and confirmed acute pancreatitis in 4 Wegovy-treated patients versus 1 on placebo.

One more fact belongs in the decision.

In SURMOUNT-4, after 36 weeks of tirzepatide (a mean loss of 20.9%), the people switched to placebo regained 14.0% by week 88, while those who continued lost a further 5.5%.

In the STEP 1 extension, one year after stopping semaglutide 2.4 mg and the lifestyle program, participants had regained about two-thirds of the weight they had lost, and cardiometabolic improvements largely reverted.

Federal rule first: Wegovy, Zepbound and Foundayo are prescription-only.

FDA's instruction is to obtain a prescription from your doctor and fill it at a state-licensed pharmacy, and that holds whichever desk you sit across.

Who that prescriber may be is state law.

For nurse practitioners, the American Association of Nurse Practitioners sorts the states into Full Practice (NPs may evaluate, diagnose and prescribe under the board of nursing alone), Reduced Practice (a career-long collaborative agreement is required for at least one element of practice) and Restricted Practice (career-long supervision, delegation or team management is required).

AANP publishes the category for each state, and which one applies to you is your state's law to answer.

Med spa procedure rules follow the same state-by-state shape.

The American Med Spa Association says injecting botulinum toxin is the practice of medicine because a prescription ("legend") drug is used to affect living tissue, so it must be done by a physician, an independent-practice NP or another licensed professional acting within their scope, under rules that vary by state.

We could not confirm a rule written specifically for GLP-1 injections at a med spa; who may give them is your state's law, and the clinic should be able to name the licensed professional responsible in your state.

An offer that skips the prescriber — medication shipped with no licensed clinician evaluating you first — is one of the patterns on FDA's red-flag list for GLP-1 sellers.

The compounded copies of semaglutide and tirzepatide entered the market while both drugs were in FDA-declared shortage, each since 2022.

That shortage basis is now gone, and 2025 was the year the last of it expired.

FDA declared the tirzepatide injection shortage resolved on October 2, 2024, and reaffirmed the resolution on December 19, 2024, after re-evaluating it during litigation.

FDA declared the semaglutide injection shortage resolved on February 21, 2025, giving 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop making essentially-copy products.

As of FDA's April 1, 2026 update, neither drug appears on the shortage list or the 503B bulks list, so outsourcing facilities generally may not compound them from bulk drug substance.

The enforcement grace periods that had allowed volume production ended by May 22, 2025.

What remains is narrow.

Under 503A, a pharmacy may still compound a copy for an individual patient when the prescriber determines and documents that a change produces a significant clinical difference for that patient.

FDA has also said it does not intend to act against a 503A compounder that fills four or fewer prescriptions of a given compounded product in a calendar month.

What compounded products are not is FDA-approved.

FDA says compounded drugs are not reviewed for safety, effectiveness or quality before marketing, and should be used only in patients whose medical needs cannot be met by an FDA-approved drug.

FDA lists claiming that a compounded drug is the same as an FDA-approved drug among its red flags for GLP-1 sellers.

FDA also says two ingredients cannot legally be used in compounding and are not components of any FDA-approved drug: retatrutide and cagrilintide.

The safety record is thin, and FDA says it is undercounted.

As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide, and notes the counts are likely underreported because 503A pharmacies are not required to report adverse events.

FDA has also received reports linked to compounded semaglutide or tirzepatide prescribed above label doses — larger doses, more frequent doses or faster titration — some serious.

One FDA example shows how quickly dosing goes wrong: a provider meant to prescribe 0.25 mg (5 units) but wrote 25 units — five times the intended dose — and the patient had severe vomiting.

Semaglutide's half-life of about one week means overdose symptoms may need prolonged observation and treatment.

There are two price tags here, and they get confused.

The drug has a published price, because both manufacturers post self-pay prices.

The program around it does not: we could not confirm any national figure for what med spas or clinics charge for a bundled weight-loss program, so the numbers below are the drugs, not the programs.

Zepbound (Eli Lilly's self-pay prices, read October 16, 2026): a 1-month supply of the single-patient-use KwikPen or of 4 vials starts at $299 for the 2.5 mg strength.

The regular KwikPen prices are $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg and $699 for the 10, 12.5 and 15 mg strengths, with a $449 purchase offer for the 7.5–15 mg strengths if each refill is bought within 45 days of the previous one.

Wegovy (Novo Nordisk's self-pay prices, read October 16, 2026): the injection is $349 a month at every dose from 0.25 mg to 2.4 mg, and $399 a month for Wegovy HD 7.2 mg; new patients pay $199 a month for the first two fills of the 0.25 mg and 0.5 mg strengths, an offer running through December 31, 2026.

The Wegovy tablet is $149 a month for 1.5 mg, $199 for 4 mg and $299 for the 9 mg and 25 mg strengths — one month means 30 tablets.

Both companies say they can change or end these offers, so read them as a snapshot from October 16, 2026.

On Medicare, Lilly's Zepbound page mentions a "Medicare GLP-1 Bridge" for eligible Medicare Part D patients prescribed Zepbound for weight management; our research could not verify the program's details, so check Medicare or your plan directly before counting on it.

When you compare program quotes, the useful questions are: does the fee include the medication or bill it separately; does it cover the prescriber visit, any lab work and follow-up contact; which pharmacy fills the prescription; and what happens to the fee if you stop.

The prescription rules do not change with the channel: a licensed prescriber, a valid prescription, a state-licensed pharmacy.

FDA's own instruction is to obtain the prescription from your doctor.

What the three settings sell around that prescription — exams, labs, check-in cadence, add-ons — follows no structure we could confirm, so judge the specific offer rather than the sign on the door.

For telehealth offers, FDA keeps a specific red-flag list for GLP-1s: claiming a compounded drug is the same as an FDA-approved drug; deep discounts that seem too good to be true; no screening and prescription by a licensed doctor; no doctor available for questions; label spelling errors or wrong pharmacy addresses; or a pharmacy name you suspect is fraudulent.

FDA is also aware of fraudulent compounded semaglutide and tirzepatide whose labels name pharmacies that do not exist, or licensed pharmacies that did not actually make the product.

The same screen works in person.

A clinic that will not name its prescriber, its pharmacy and what its monthly fee buys is telling you something.

In any setting, ask whether the prescriber will review your full history and your other medicines: the labels' contraindications, pregnancy rules and birth-control advice depend on them.

Search results for a weight loss clinic near you will mix med spas, telehealth brands and medical practices, and the checks below are the same for all three.

None of them requires medical knowledge:

Who may evaluate, prescribe and follow up is state law, so the prescriber's license and the state that issued it are worth verifying wherever the clinic is.

If any part of an offer skips the prescription — the evaluation, the prescriber, the pharmacy — that is the pattern FDA's guidance describes.